［1］唐刚华. 肿瘤氨基酸代谢正电子发射断层显像［J］. 第一军医大学学报,2002,22(12增刊):74-78.
［2］Laverman P, Boerman O C, Corstens FHM, et al. Fluorinated amino acids for tumour imaging with positron emission tomography［J］. Eur J Nucl Med, 2002, 29: 681-690.
［3］Jager P L, Vaalburg W, Pruim J, et al. Radiolabeled amino acids: basic aspects and clinical applications in oncology［J］. J Nucl Med, 2001, 42:432-445.
［4］Huang C, McConathy J. Radiolabeled amino acids for oncologic imaging［J］. J Nucl Med, 2013, 54(7): 1007-1010.
［5］McConathy J, Yu W, Jarkas N, et al. Radiohalogenated nonnatural amino acids as PET and SPECT tumor imaging agents［J］. Med Res Rev, 2012, 32(4): 868-905.
［6］Mampassi D M,顾月清. 与肿瘤有关的氨基酸代谢缺陷及其相关药物的应用［J］. 药物生物技术,Pharm Biotech, 2012,19(4): 373-376.
［7］Kanal Y, Endou H. Functional properties of multispecific amino acid transporters and their implications to transporter-mediated toxicity［J］. J Toxicol Sci, 2003, 28(1): 1-17.
［8］Palacin M, Estevez R, Bertran J, et al. Molecular biology of mammalian plasma membrane amino acid transporters［J］. Physiol Rev, 1998, 78(4): 969-1054.
［9］McConathy J, Goodman M M. Non-natural amino acids for tumor imaging using positron emission tomography and single photon emission computed tomography［J］. Cancer Metastasis Rev, 2008, 27: 555-573.
［10］Vaalburg W, Coenen H H, Crouzel C, et al. Amino acids for the measurement of protein synthesis in vivo by PET［J］. Int J Rad Appl Instrum B, 1992, 19(2):227-237.
［11］何山震,王淑侠,王朋,等. ¹⁸F和¹¹C标记的氨基酸类分子探针的合成及应用研究进展［J］. 核技术,2014,37(8):080302-1-080302-7.
［12］Deng H, Tang X, Wang H, et al. S-［¹¹C］methyl-L-cysteine, ［¹¹C］MCYS: A new amino acid PET tracer for cancer imagimg［J］. J Nucl Med, 2011, 52: 287-293.
［13］Burger I A, Zitzmann-Kolbe S, Pruim J, et al. First clinical results of (D)-¹⁸F-fluoromethyltyrosine (BAY 86-9596) PET/CT in patients with non-small cell lung cancer and head and neck squamous cell carcinoma［J］. J Nucl Med, 2014, 55: 1778-1785.
［14］ Huang T, Tang G, Wang H, et al. Synthesis and preliminary biological evaluation of S-¹¹C-methyl-D-cysteine as a new amino acid PET tracer for cancer imaging［J］. Amino Acids, 2015, 47: 719-727.
［15］ Huang C, McConathy J. Fluorine-18 labeled amino acids for oncologic imaging with positron emission tomography［J］. Current Top Med Chem, 2013, 13: 871-891.
［16］Wu Z, Zha Z, Li G, et al. ［¹⁸F］(2S, 4S)-4-(3-Fluoropropyl)glutamine as a tumor imaging agent［J］. Mol Pharm, 2014,11(11): 3852-3866
［17］Tang G, Wang M, Tang X, et al. Synthesis and evaluation of O-(3-［¹⁸F］fluoropropyl)- L-tyrosine as an oncologic PET tracer［J］. Nucl Med Biol, 2003, 30(7): 733-739.
［18］He S, Tang G, Hu K, et al. Radiosynthesis and biological evaluation of 5-(3-［¹⁸F］fluoropropyloxy)-L-tryptophan for tumor PET imaging［J］. Nucl Med Biol, 2013, 40(6): 801-807.
［19］  berg K. Molecular imaging radiotherapy: Theranostics for personalized patient management of neuroendocrine tumors (NETs)［J］. Theranostics, 2012, 2(5): 448-458.
［20］Wilcox C E, Braskie M N, Kluth J T, et al. Overeating behavior and striatal dopamine with 6-［¹⁸F］-Fluoro-L-m-tyrosine PET［J］. J Obesity, 2010: 6.
［21］Baek S, Mueller A, Lim Y S, et al. (4S)-4-(3-¹⁸F-Fluoropropyl)-L-glutamate for imaging of xC^-  transporter activity in hepatocellular carcinoma using^P ET: preclinical and exploratory clinical studies［J］. J Nucl Med, 2013, 54: 117-123.
［22］Venneti S, Dunphy M P, Zhang H, et al. Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo［J］. Sci Transl Med, 2015, 7: 274-17.
［23］Langena K J, Muhlensiepen H, Schmieder S, et al. Transport of cis- and trans-4-［¹⁸F］fluoro-L-proline in F98 glioma cells［J］. Nucl Med Biol, 2002, 29: 685-692.
［24］Ploess K, Wang L, Lieberman B P, et al. Comparative evaluation of ¹⁸F-Labeled glutamic acid and glutamine as tumor metabolic imaging agents［J］. J Nucl Med, 2012, 53: 1616-1624.
［25］Prenant C, Theobald A, Haberkorn U, et al. Feasibility of labeled α-acetamido-aminoisobutyric acid as new tracer compound for kinetic labeling of neutral amino acid transport: preparation of (α-(N-［-¹¹C］acetyl) and α-(N-［1-¹⁴C］acetyl)-aminoisobutyric acid［J］. Nucl Med Biol, 1996, 23: 359-363.
［26］Awasthi V, Pathuri G, Agashe H B, et al. Synthesis and in vivo evaluation of p-¹⁸F-fluorohippurate as a new radiopharmaceutical for assessment of renal function by PET［J］. J Nucl Med, 2011, 52: 147-153.
［27］Hu K, Du K, Tang G, et al. Radiosynthesis and biological evaluation of N-［¹⁸F］labeled glutamic acid as a tumor metabolic imaging tracer［J］. Plos One, 2014, 9(3): 1-9.
［28］Krasikova R N, Kuznetsova O F, Fedorova O S, et al. 4-［¹⁸F］Fluoroglutamic Acid (BAY 85-8050), a new amino acid radiotracer for PET imaging of tumors: synthesis and in Vitro characterization［J］. J Med Chem, 2011, 54: 406-410.
［29］Ermert J, Coenen H H. Methods for ¹¹C and ¹⁸F-labelling of amino acids and derivatives for positron emission tomography imaging［J］. J Label Compd Radiopharm, 2013, 56: 225-236.
［30］Stenhagen ISR, Kirjavainen A K, Forsback S J, et al. ［¹⁸F］Fluorination of an arylboronic ester using［¹⁸F］selectfluor bis(triflate): application to 6-［¹⁸F］fluoro-L-DOPA［J］. Chem Commun, 2013, 49: 1386-1388.
［31］Wagner F M, Ermert J, Coenen H H. Three-step,“one-pot” radiosynthesis of 6-fluoro-3, 4-dihydroxy-l-phenylalanine by isotopic exchange［J］. J Nucl Med, 2009, 50: 1724-1729.
［32］Libert L C, Franci X, Plenevaux A R, et al. Production at the curie level of no-carrier-added 6-¹⁸F-fluoro-l-dopa［J］. J Nucl Med, 2013, 54: 1154-1161.
［33］Tredwell M, Preshlock S M, Taylor N J, et al. A general copper-mediated nucleophilic ¹⁸F-fluorination of arenes［J］. Angew Chem Int Ed, 2014, 53: 7751 -7755.
［34］唐刚华. 多巴胺神经递质系统正电子发射断层显像［J］. 中华神经科杂志,2002,35(5):603,703.
［35］Wilcox C E, Braskie M N, Kluth J T, et al. Overeating behavior and striatal dopamine with 6-［¹⁸F］-fluoro-L-m-tyrosine PET［J］. J Obesity, 2010, 2010: 6.
［36］Ito H, Takano H, Arakawa R, et al. Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-［β-11C］DOPA［J］. Plos One, 2012, 7(9): e46488.
［37］Lapa C, Linsenmann T, Monoranu C M, et al. Comparison of the amino acid tracers ¹⁸F-FET and ¹⁸F-DOPA in high-grade glioma patients［J］. J Nucl Med, 2014, 55: 1611-1616.
［38］Morooka M, Kubota K, Kadowaki H, et al. ¹¹C-Methionine PET of acute myocardial infarction［J］. J Nucl Med, 2009, 50: 1283-1287.
［39］Bhutia Y D, Babu E, Ramachandran S, et al. Amino acid transporters in cancer and their relevance to “glutamine addiction”: novel targets for the design of a new class of anticancer drugs［J］. Cancer Res, 2015, 75(9): 1782-1788.